• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Precision medicine in gastric cancer

    2019-10-23 05:37:58PatriziaBonelliAntonellaBorrelliFrancaMariaTuccilloLucreziaSilvestroRaffaelePalaiaFrancoMariaBuonaguro

    Patrizia Bonelli,Antonella Borrelli,Franca Maria Tuccillo,Lucrezia Silvestro,Raffaele Palaia,Franco Maria Buonaguro

    Patrizia Bonelli,Antonella Borrelli,Franca Maria Tuccillo,Franco Maria Buonaguro,Molecular Biology and Viral Oncology,Istituto Nazionale Tumori - IRCCS - Fondazione G Pascale,Napoli 80131,Italy

    Lucrezia Silvestro,Abdominal Medical Oncology,Istituto Nazionale Tumori - IRCCS -Fondazione G Pascale,Napoli 80131,Italy

    Raffaele Palaia,Gastro-pancreatic Surgery Division,Istituto Nazionale Tumori - IRCCS -Fondazione G Pascale,Napoli 80131,Italy

    Abstract

    Key words: Gastric cancer; Molecular characterization; Biomarkers; Precision medicine;Targeted therapy

    INTRODUCTION

    Gastric cancer (GC) is a complex disease whose onset is linked to a series of genetic and environmental factors such as smoking and a high salt diet.Helicobacter pylori(H.pylori) is considered one of the most significant risk factors of GC.It is present in more than 70% of non-cardia GC cases and 90% of chronic gastritis cases[1],and its presence increases the risk of cancer (as compared to uninfected individuals)[2,3].Recent research has shown that there is a correlation between the risk of GC and the characteristics of specific strains ofH.pylori[4].Moreover,H.pyloriinfection has been demonstrated to be essential for promoting chronic inflammation of the gastric epithelium and histological changes that sequentially lead to GC[5].In this process,genetic and epigenetic alterations occur such as hypermethylation of DNA or mutations in genes including APC,WNT signaling pathway regulator (APC),tumor protein p53 (TP53),and KRAS proto-oncogene,GTPase (KRAS)[6].

    Regarding treatment options,surgical resection with adjuvant or neoadjuvant radiotherapy and chemotherapy with cisplatin,5-fluorouracil (5-FU),taxane,or irinotecan are the most effective treatments for GC.However,despite the increasing knowledge and progress in drug development,this disease has a very poor prognosis due to late diagnosis and extreme intra- and inter-tumor heterogeneity.The heterogeneity makes the choice of therapy difficult,emphasizing the need for both new indicators for patient classification and novel therapies capable of addressing genetic,molecular,and cellular heterogeneity within tumors.This review highlights the progress achieved in the molecular characterization of GC and how it has impacted diagnosis,prognosis,and therapy in clinical practice.

    EPIDEMIOLOGY OF GC

    GC is the fifth most malignant tumor in worldwide and the third leading cause of cancer-related deaths[7].Unfortunately,the disease becomes symptomatic in the advanced stage; thus,the 5-year survival rate is only high (90%) in Japan where diagnosis and early tumor resection are done[8].In European countries,however,the survival rate is low,varying between 10% and 30%[9].The incidence of GC has geographical variation,with more than 50% of new cases occurring in developing countries.The areas most at risk are represented by China and Japan,Eastern Europe,Central,and South America,while the areas with lowest risk are South Asia,North America,New Zealand,Australia,and North and East Africa[10].In recent decades,a decrease in the incidence rate has been observed,especially in young patients with non-cardia,sporadic,and intestinal GC[11,12].The decreased incidence of GC can be attributed to the better preservation of foods,higher hygienic standards,higher intake of fruits and vegetables,and the eradication ofH.pylori[13].Figure1 summarizes the epidemiology of GC.

    PATHOLOGICAL CLASSIFICATION OF GC

    According to World Health Organization (commonly known as WHO) guidelines,GC can be classified as adenocarcinoma,ring-cell carcinoma,and undifferentiated carcinoma[14].The Lauren's classification,which is widely used,classifies GC into intestinal,diffuse,and mixed/unclassified types based on macroscopic and microscopic differences[15].It has been hypothesized that intestinal GC is associated with chronic atrophic gastritis and intestinal metaplasia,whereas the diffuse type originates from normal gastric mucosa.In European countries,the intestinal type is currently the most common GC[16-20].It tends to occur more often in the distal part of the stomach,in high-risk areas and is often preceded by long-standing precancerous lesions[17].On the other hand,the diffuse type is predominant among young patients.However,Lauren’s classification has a couple of key flaws.First,a large group of carcinomas do not fall into the two main types of carcinomas,intestinal or diffuse.This group of “unclassified” or “undetermined” gastric carcinomas include undifferentiated carcinomas and carcinomas that have dual differentiation (mixed intestinal and diffuse carcinomas).Second,there has been confusion regarding the“intestinal” term.Therefore,a change to Lauren’s classification has been proposed in which GCs are classified into four subtypes:Glandular,solid,isolated cell type,and mixed carcinoma[21].

    MOLECULAR CHARACTERIZATION OF GC

    Advances in next-generation sequencing (NGS) and microarray technologies and a better understanding of cancer biology have provided opportunities to characterize the genome of tumors including GC.The molecular profile of the GC has enabled The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) to classify GC into subtypes.The new molecular classification of GC is complementary to the subtyping classification based on histopathological characteristics.It is important to note that the molecular classification of GC helps to identify the molecular alterations that may be targeted by therapy.Furthermore,the molecular profiles of GCs obtained from individual patients have offered new opportunities to identify biomarkers that can be predictive of the tumor response to treatment[22-24]and to guide the selection of cytotoxic drugs and targeted therapies.TCGA and ACRG classifications of GC should facilitate the development of personalized prognosis and treatment,as well as better patient stratification for the design of clinical trials.The molecular characterization of GC from TCGA has used different platforms,including exome sequencing,DNA copy number analysis,DNA methylation,mRNA and microRNA (miRNA) expression.It divides GC into four subtypes:Epstein-Barr virus(EBV)-positive,microsatellite instable (MSI),chromosomal instability (CIN),and genomically stable (GS) (Figure2).Each of these GC subtypes is characterized by distinct features that provide prognostic information and suggest the potential benefits of targeted therapy.

    EBV-positive tumors have mainly been found in the fundus and gastric body[25,26],and represent about 9% of GC cases.High DNA hypermethylation has been demonstrated in EBV-positive tumors,particularly of the cyclin-dependent kinase inhibitor 2A (commonly known asCDKN2A) promoter[27].An estimated 80% of EBV-positive subtype tumors contain mutations in phosphatidylinositol 3-kinase CA(PIK3CA)[28]and amplification of Janus Kinase 2 (JAK2),CD274 molecule,and programmed cell death 1 ligand 2 (PDCD1LG2),which encode for respectively tyrosine kinase receptors,PD-L1 and PD-L2[29].Based on these results,JAK2 inhibitors and PD-L1/2 antagonists should be explored as treatment options for EBV-positive tumors.Promising initial results have been reported with pembrolizumab,a humanized monoclonal antibody against programmed cell death 1 (PD-1)[30,31].In addition toPIK3CAmutations,EBV-positive tumors have more recurrent AT-rich interaction domain 1A (ARID1A) (55%) and BCL6 corepressor (commonly known asBCOR) (23%) mutations[29,32],whereas only rareTP53mutations have been observed.

    Figure1 Epidemiology of gastric cancer.Frequency of diagnosis,leading cause of cancer death,and risk areas worldwide of gastric cancer.

    Patients with MSI subtype generally have intestinal tumors,which are diagnosed in old age.MSI tumors (21.7% of GC cases) are characterized by genomic instability due to methylation of DNA mismatch repair genes including MutL homolog 1 (MHL1)and to a high incidence of mutations inPIK3CA[33],Erb-B2 receptor tyrosine kinase 3(ERBB3)[34],ring finger protein 43 (RNF43)[35],phosphatase and tensin homolog(PTEN)[36],TP53[37],KRAS[38],andARID1A[32]genes.Increased expression of components of the mitotic pathway such as the E2F transcription factor (E2F),aurora kinase A (AURKA),polo-like kinase 1 (PLK1),and forkhead box M1 (FOXM1) has been described in MSI tumors[29].

    GS tumors (19.7%) are mainly diffuse and are diagnosed in younger patients[39].GS tumors,which lack chromosomal alteration or MSI,exhibit the high expression of molecules involved in cell adhesion and pathways related to angiogenesis.They also have low mutation rates andARID1A,ras homolog family member A (RHOA),and cadherin 1 (CDH1) are the most frequently mutated genes[40].Previous studies have shown the loss ofCDH1,which encodes the E-cadherin cell adhesion molecule,in hereditary diffuse GC[41].TCGA data have also revealed the fusion of claudin 18-Rho GTPase activating protein 6 (CLDN18-ARHGAP6) or claudin 18-Rho GTPase activating protein 26 (CLDN18-ARHGAP26) and recurrent mutations inRHOA.CLDN18 and ARHGAP6 are respectively involved in the intercellular structure of the tight junction and the activation of Rho signaling (a signaling pathway in which intracellular and extracellular stimuli activate GTPase Rho),whereas RHOA modulates programmed cell death and contractility and motility of actomyosindependent cells[42-44].Therefore,alterations in RHOA or CLDN18-ARHGAP6 could contribute to the lack of cell cohesion,dispersed growth,and programmed cell death resistance.

    CIN tumors represent almost half of GC cases (49.8%),are mainly intestinal,and are most frequent in the cardia-gastro-esophageal junction.Chromosomal deletions affectingCDH1,catenin alpha 1 (CTNNA1) and RB transcriptional corepressor 1 (RB1)and mutations inTP53(71%) are frequent in these tumors.CIN tumors present with amplification of genes encoding tyrosine kinase receptors such as epidermal growth factor receptor (EGFR),ERBB2,ERBB3,fibroblast growth factor receptor 2 (FGFR2),and MET proto-oncogene,receptor tyrosine kinase (MET); some transcription factors including the MYC proto-oncogene,basic helix-loop-helix transcription factor (MYC)and GATA binding protein 4 (GATA4); cell cycle regulators such as cyclin-dependent kinase 6 (CDK6),cyclin E1 (CCNE1),and cyclin D1 (CCND1) and other genes such asPDCD1LG2andPIK3CA[29].Alterations of these genes have been observed in advanced/metastatic GC[24].By contrast,the ACRG analyzed samples from 300 Korean patients,classifying GC based on particular genetic signatures such as the activation status ofTP53and the MSI condition[45].Four molecular subtypes have been identified:MSI,microsatellite stable (MSS) with activeTP53(MSS/TP53+),MSS with inactiveTP53(MSS/TP53-),and MSS with epithelial-mesenchymal transition (EMT)signature (MSS/EMT) (Figure3).

    Figure2 The Cancer Genome Atlas gastric tumor classification.TCGA study divides GC into four molecular subtypes:CIN (chromosomal instability); EBV (Epstein-Barr virus); GS (genomically stable); and MSI (microsatellite instable).GC:Gastric cancer; TCGA:The Cancer Genome Atlas.

    These subtypes are associated with survival and recurrence.The MSI subtype has a better prognosis and a lower tendency to relapse.The MSS/TP53+ and MSS/TP53-subtypes have an intermediate prognosis,whereas the MSS/EMT subtype is associated with a high rate of recurrence and a lower survival rate.Moreover,MSI tumors are diagnosed at an early stage (I/II),and about 60% are intestinal and show a high frequency of mutations ofPIK3CA,KRAS,ARID1A,and ALK receptor tyrosine kinase (ALK) genes; they also show loss ofMLH1.Tumors of the MSS/TP53+ subtype include many EBV-positive cases compared to the other subtypes,and have a high prevalence of mutations in theAPC,KRAS,PIK3CA,ARID1A,and SMAD family member 4 (SMAD4) genes[46]compared to the MSS/TP53- subtype.They also present amplification of theCCNE1gene.The MSS/TP53- subtype is mainly Lauren intestinal and hasTP53mutations,with a low frequency of mutations affecting the other genes.This subtype also has amplification ofEGFR,MYC,ERBB2,andCCNE1genes.The MSS/EMT subtype predominantly consists of Lauren diffuse tumors,and tend to be diagnosed at a younger age.This subtype has low cell adhesion due to loss ofCDH1and has the least number of mutations.ARID1Ais among the most frequently mutated gene.The ACRG classification is also applicable to other large independent cohorts[45].The differences between the two classifications (TGCA and ACRG) reflect the different approaches and platforms used,and the ethnicity of the samples.In the ACRG cohort,GCs of the diffuse type are more represented.However,both identified the MSI subtype with hypermethylation ofMHL1,high mutation frequency and a better prognosis.The EBV and MSS/TP53 + subtypes are similar in that many cases belonging to the MSS/TP53+ subtype is EBV+ and present mutations inPIK3CAandARID1A.The GS and MSS/EMT subtypes,which include younger patients,are mostly diffuse and show low intercellular adhesion.The CIN and MSS/TP53-subtypes present with mutations inTP53and amplification of members of theEGFRfamily,and are mostly intestinal.

    APPLICATION OF THE GC MOLECULAR PROFILE IN CLINICAL PRACTICE:PRECISION MEDICINE

    Due to new technologies,such as NGS and microarray,recent discoveries have made possible to integrate diagnostic and therapeutic method,based on genotype and phenotype,and to apply them to individual patients with GC in the age of precision medicine.

    Figure3 Asian Cancer Research Group gastric tumor classification.Gastric cancer was classified into foursubtypes:MSI (microsatellite instable); MSS (stable microsatellite); MSS/TP53+ (MSS with active TP53); MSS/TP53-(MSS with inactive TP53); MSS/EMT (MSS with epithelial-mesenchymal transition).ACRG:Asian Cancer Research Group.

    Biomarkers for diagnosis and prediction

    Tumor markers are used to determine the clinical stage,assess the treatment response,and predict the risk of recurrence after treatment.Currently,markers such as αfetoprotein (AFP),carcinoembryonic antigen (CEA),carbohydrate antigen 125 (CA-125),and carbohydrate antigen 19-9 (CA19-9) are frequently used in clinical practice.CEA is a risk factor for liver metastases[47],and increased CEA levels have been observed in all advanced GCs.The sensitivity and specificity of CEA for predicting GC recurrence is < 60% and < 80%,respectively[48].CA19-9 is a marker commonly used in GC,although it is also present in other neoplastic pathologies.In combination with other tumor markers,CA19-9 can provide more information to predict GC recurrence[49].Other markers such as AFP and CA-125 are widely used in the diagnosis of GC.AFP is an indicator of a high stage and presence of hepatic metastases[50],and CA-125 is associated with peritoneal diffusion[47].

    Among the new biomarkers,human epidermal growth factor receptor 2 (encoded byERBB2commonly referred to asHER2) represents the first biomarker available in clinical practice for patients with GC.HER2 belongs to the EGFR family and has tyrosine kinase activity[51].An estimated 6%-23% of GCs have overexpression and/or amplification ofHER2[52,53],and it is mainly found in intestinal tumors[54,55].HER2 is used in clinical practice for targeted therapy.EGFR or ERBB1 is expressed in about 30% of GCs[56].The overexpression of EGFR in the pathogenesis of GC is associated with a poorly differentiated histology,vascular invasion,and shorter survival[57].Tyrosine kinase inhibitors,particularly gefitinib and erlotinib,have shown efficacy inEGFR-amplified tumors.Mutations ofEGFRconfer resistance to these drugs[58,59].In addition to anti-HER2 monoclonal antibodies,anti-EGFR therapy also includes gefitinib and erlotinib,tyrosine kinase inhibitors,as well as monoclonal antibodies such as cetuximab and panitumumab.

    Other markers have attracted substantial attention as useful therapeutic candidates for targeted anti-cancer agents.For example,a high frequency (30%) of FGFR2 overexpression has been observed in GC.The amplification ofFGFR2is related to poor overall survival (OS)[60].Furthermore,a study found that FGFR2 could be a biomarker for predicting the long-term failure of adjuvant chemotherapy for advanced GC[61].Thus,FGFR2 may be a candidate for targeted anticancer agents.E-cadherin,a molecule involved in calcium-mediated cell adhesion,is a tumor suppressor whose deactivation is correlated with invasion and metastasis[62].The deactivation ofCDH1may occur due to mutations,hypermethylation,loss of heterozygosity,andH.pyloriinfection[62].Patients withCDH1changes have generally worse survival than negative patients.It could be a useful marker for the diagnosis of preoperative biopsies[63].Genetic deregulation of the PI3K/AKT/mTOR pathway has been frequently identified in GC[64,65],and mechanistic target of rapamycin kinase(mTOR) is activated in 60% of GCs[66].

    Mutations ofPI3KCA,which encodes the p110α catalytic isoform of PI3K,have been identified in up to 25% of patients with GC[67].These mutations are involved in resistance to antitumor drugs and the acquisition of a metastatic phenotype;moreover,they are found mainly in the EBV-positive subtype of GC[68].It has been reported that the amplification and/or overexpression ofMETis involved in carcinogenesis,the efficacy of therapy,and the outcome of GC[69].MET expression is associated with invasion and overall poor survival[70].Vascular endothelial growth factor (VEGF) encodes for a growth factor that promotes the formation of new blood vessels.VEGF and vascular endothelial growth factor receptor (VEGFR) are upregulated in about 40% of GC cases[71],and their inhibition results in decreased cell proliferation and invasion.VEGF andsVEGFR2 are also used in clinical practice in targeted therapy[72,73].TP53is a tumor suppressor whose incidence of mutation in GC is about 3%-65%[74].In the EBV-positive subtype,the incidence ofTP53mutation is lower[28]; moreover,an increased incidence has been observed in the intestinal type[75].In many human tumors,TP53mutations are associated with a poor prognosis[76].For GC,there is no well-established clinical significance between theTP53status and the outcome of patients.Recent studies,however,have integrated the mutational status ofTP53and other genetic alterations to define subpopulations of GCs in order to define the clinical relevance[77].TP53mutations appear to be a cofactor that supports the expression of genes involved in various signaling pathways; and whose aberrant activation leads to high proliferation,increased metastatic potential,and resistance to treatment.AURKAand MDM2 proto-oncogene (MDM2) encode negative regulators ofTP53.AURKAis amplified and overexpressed in GC[78].By regulating the ubiquitination of TP53 through MDM2,AURKA promotes tumor growth and cell survival[79].

    DNA damage is repaired by a series of mechanisms,including basic excision repair,mismatch repair,nucleotide excision repair,single-strand annealing,homologous recombination,and non-homologous end joining.The poly (ADP-ribose)polymerases,known as PARPs,are proteins involved in the basic excision repair pathway and catalyze the transfer of ADP-ribose to target proteins[80,81].PARP1 and PARP2 are the best known of these proteins.Numerous studies have highlighted an upregulation of PARPs in different tumors,including GC[82,83].A high expression of PARP1 in GC is associated with tumor invasion and a poor prognosis[84].

    Proteins in the matrix metalloproteinase (MMP) family are involved in breakdown of the extracellular matrix in normal physiologic processes and can promote cancer cell invasion and metastasis by degrading the extracellular matrix.Increased matrix metallopeptidase 15 (MMP15) expression is associated with poor prognosis in GC[85].In addition,overexpression of matrix metallopeptidase 9 (MMP9)is a poor prognostic factor in patients with GC[86].

    Fibrinogen C domain containing 1 (FIBCD1) is an acetyl group-binding receptor,which shows high affinity and calcium-dependent binding to acetylated structures such as chitin,some N-acetylated carbohydrates,and amino acids but not to their non-acetylated counterparts.The expression ofFIBCD1is significantly increased in GC tissues compared with normal tissues,and its overexpression is related to a poor prognosis[87].FIBCD1 may be a novel prognostic marker in gastric GC; however,the mechanisms underlying its function require further studies.

    PD-1 and PD-2 are the immune checkpoint receptors expressed on T and B lymphocytes,natural killer T cells,and monocytes[88].After binding with PD-L1 and PD-L2 on activated T cells,they downregulate the activity of cytotoxic T cells and thus induce immunotolerance to the tumor.In 15%-70% of patients with GC,PD-L1 expression has been observed and this expression correlates with poor outcome[89].Upregulation ofPD-L1/PD-L2expression in the EBV-positive subtype has been observed[29].

    Circulating tumor cells (CTCs),single or in clusters,originate from primary tumor or metastases[90].Clinically,they are related to the progression and metastatic processes,and therefore can be used as surveillance markers.CTCs can identify early stages of metastasis and thus identify patients who may benefit from treatment after primary tumor surgery[90,91].The presence of CTCs,which have the characteristics of stem cell-like or EMT cells,allows evaluation of the tumor stage and the prediction of recurrence.Circulating cell-free DNA is more sensitive than CTCs,originates from normal and cancerous cells,and is present in the blood[92].Circulating tumor DNA(ctDNA) originates from the primary tumor or metastases and can be used for the specificity of the diagnosis,even if the sensitivity is lower than the common markers used[93].The ctDNA shows the presence of EBV DNA,and is useful for identifying EBV-positive subtypes[94].The response to therapy can also be assessed with ctDNA.

    MiRNAs are small,non-coding RNAs that,by regulating gene expression,play a role in the processes of proliferation,differentiation,and cell invasion[95].They can increase the expression of oncogenes or reduce the expression of oncosuppressor genes[96].Numerous miRNAs have been identified and play a role in GC[97,98].Circulating cell-free miRNAs can be used as non-invasive biomarkers for the diagnosis and relapse of GC[99-101].Approximately 135 long non-coding RNAs(lncRNAs),non-transcribed RNA sequences longer than 200 nucleotides,are dysregulated and strongly correlated with tumorigenesis,metastasis,and prognosis of GC[102-103].Some lncRNAs are overexpressed in GC compared to healthy control tissue and may be prognostic markers[104,105].However,further studies are needed to determine their possible clinical use.

    Biomarkers for targeted therapy

    Surgery is the elective treatment for many stages of GC.In a patient with GC at stage 0,I,II,or III,surgery (often together with other treatments) is currently the only treatment.Depending on the type and stage of GC,it is possible with surgery to remove all or part of the stomach including the nearby lymph nodes (the principles).Even when the tumor is too widespread to be removed entirely,patients can be helped by surgery because it can help prevent bleeding from the tumor or remove stomach obstruction due to tumor growth.This is termed palliative surgery because it allows the reduction or prevention of symptoms,but is not indicated for the treatment of GC[106].

    Minimally invasive surgery,including laparoscopic gastrectomy and robotic gastrectomy,is receiving much attention in GC management[107,108].The laparoscopic gastrectomy has the advantage of leading to a faster recovery with shorter hospital stays compared to the traditional surgery[109].However,it has the disadvantage of limited movements.The robotic gastrectomy has overcome these limitations and its use is spreading rapidly[110-112].Some studies have been carried out in order to compare both the advantages and disadvantages of two technologies[113-115].The disadvantages of robotic gastrectomy concern its cost,duration of the procedure,and training needs[116].Unfortunately,the lack of controlled and randomized studies has precluded the ability to establish a clear indication of robotic gastrectomy in the treatment of GC[116].

    Surgical resection with pre- and post-operative chemotherapy and/or radiotherapy is the primary curative treatment of early-stage GC with a 5-year survival of about 30%[117-119].Systemic chemotherapy is used to treat patients with localized and advanced GC.Palliative systemic therapy and chemo/radiotherapy are standard treatment options for patients with unresectable or metastatic advanced GC.Neoadjuvant chemotherapy with surgery is associated with the improved survival of patients with metastatic disease[120].Perioperative chemotherapy with docetaxel,oxaliplatin,fluorouracil,and leucovorin (FLOT) significantly improves progressionfree survival (referred to herein as PFS) and OS among patients with resectable GC compared with epirubicin,cisplatin,and fluorouracil or capecitabine (ECF/ECX)[121].A Bayesian network meta-analysis obtained an estimate of the efficacy of perioperative FLOT and neoadjuvant treatments for resectable GC.Compared with surgery alone,perioperative cisplatin with fluorouracil (CF),perioperative ECF/ECX,and perioperative FLOT significantly improved survival.The most effective neoadjuvant treatment for the disease is likely to be perioperative FLOT[122].Targeted therapy,a new therapeutic strategy,may improve the survival of patients with advanced GC.Clinical trials with targeted therapies have been performed in patients with GC.Table1 shows some clinical trials,completed or ongoing,classified by specific molecular target.

    EGFR signaling pathway

    The EGFR signaling pathway is activated in the GC[56,123].Overexpression of EGFR has been associated with reduced OS[56,71].This behavior may depend on the observation that EGFR targeting molecules may be potential agents for target therapy.Trastuzumab is the first molecular targeted agent approved as standard therapy for GC.It is a monoclonal antibody against HER2,which binds to the extracellular domain of the receptor.A phase III clinical trial (ToGA) (NCT01041404) enrolled 594 patients with GC who had high HER2 expression.These patients were randomized to chemotherapy alone or combined with trastuzumab.Treatment with trastuzumab led to an increase in OS of 2.7 mo and the PFS was heightened compared to that of patients treated with chemotherapy alone[124].The benefits observed in patients treated with the combination of trastuzumab and chemotherapy were even more evident in patients who expressed high levels of HER2 compared to those with low HER2 expression.The 2015 National Comprehensive Cancer Network guidelines recommended the first-line treatment of trastuzumab combined with chemotherapy in patients overexpressing HER2.To date,trastuzumab is the only targeted therapy allowed for the treatment of advanced GC[124].A clinical trial (NCT01736410),which evaluated the efficacy of trastuzumab with tegafur,gimeracil,oteracil (TS-1) and cisplatin as first-line treatment for advanced HER2-positive GC,has been completed.The combination of trastuzumab with TS-1 and cisplatin demonstrated good activity,was well tolerated,and is a first-line treatment that can be used for advanced HER2-positive GC[125].In the GATSBY multicenter phase II/III study (NCT01641939),the efficacy of trastuzumab emtansine was evaluated in patients with advanced HER2-positive GC who had already received previous treatment.The results obtained werenot encouraging since treatment with trastuzumab emtansine did not yield increases in OS compared to standard treatment with a taxane (docetaxel,paclitaxel)[126].

    Table1 Clinical trials classified on molecular targets

    PI3KCA Alpelisib +AUY922 NCT01613950 Multicenter,open-label Second/third Ib Advanced/m etastatic gastric cancer,PIK3CA mutations and/or HER2 amplification Completed [145]AKT Ipatasertib ±5FU/oxaliplat in/leucovorin NCT01896531 Randomized,double Second II Advanced/m etastatic gastric cancer Active [146]HGF/MET HGF Rilotumumab vs rilotumumab±epirubicin/cis platin/capecit abine NCT00719550 Multicenter,randomized First Ib/II Locally advanced/me tastatic gastric cancer Completed [149]HGF Rilotumumab±epirubicin/cis platin/capecit abine RILOMET-1(NCT0169707 2)Multicenter,randomized,triple First III Locally advanced/me tastatic gastric cancer,MET-positive Terminated [150]HGF Rilotumumab±/cisplatin/ca pecitabine RILOMET-2(NCT0213734 3)Multicenter,randomized,triple First III Advanced gastric cancer Terminated [151]MET Onartuzumab± 5-FU/leucovori n/oxaliplatin NCT01662869 Multicenter,randomized,double First III Metastatic gastric cancer,HER2 negative,MET-positive Completed [152]VEGF/VEG FR VEGFR2 Ramucirumab+ BSC vs placebo +BSC REGARD(NCT0091738 4)Randomized,quadruple First III Metastatic/lo cally recurrent gastric cancer Completed [72]VEGFR2 Ramucirumab± paclitaxel RAINBOW(NCT0117066 3)Multicenter,randomized,double Second III Metastatic,refractory gastric cancer Completed [73]VEGFR2 Apatinib vs placebo NCT01512745 Randomized,quadruple Third III Advanced/m etastatic refractory gastric cancer Completed [156]TP53 TP53 Polymorphis ms of xenobiotic metabolism,DNA repair,and TP53 genes NCT01470404 Gastric cancer treated with adjuvant chemotherap y Completed [161]TP53 APR-246 + 5-FU/cisplatin NCT02999893 Open-label Second I/II Advanced/m etastatic platinum resistant gastroesopha geal cancer,TP53 mutated Recruiting [167]TP53 AZD1775(WEE inhibitor) +paclitaxel NCT02448329 Single center Second II Advanced gastric cancer,TP53 mutated Recruiting [169]TP53 HDM201(inhibitor TP53/MDM2 interaction)NCT02143635 Multicenter,nonrandomized,open-label Second I Advanced/m etastatic gastric cancer,TP53 wildtype Active [170]PARP PARP Olaparib +paclitaxel vs paclitaxel Study 39(NCT0106351 7)Multicenter,randomized,double Second II Metastatic/re current gastric cancer,low ATM expression Active [174]PARP Olaparib +paclitaxel vs placebo +paclitaxel GOLD(NCT0192453 3)Multicenter,randomized,double Second III Advanced gastric cancer Active [175]

    EGFR:Epidermal growth factor receptor; mTOR:Mechanistic target of rapamycin kinase; HGF:Hepatocyte growth factor; VEGF:Vascular endothelial growth factor; TP53:Tumor protein p53; PARP:Poly (ADP-ribose) polymerase; PD-1:Programmed cell death 1.

    Other agents that target HER2,such as pertuzumab and lapatinib,have been used in clinical trials in patients with advanced GC and HER2 overexpression.One study(JACOB,NCT01774786) was performed with pertuzumab,trastuzumab,and chemotherapy in patients with untreated HER2-positive metastatic GC.This trial was the first to investigate the dual antibody blockade of HER2.Unfortunately,no significant improvement in OS was observed in the dual blockade group[127].The clinical trial (TRIO-013/LOGiC,NCT00680901) performed with lapatinib in combination with oxaliplatin and capecitabine did not produce significant results in terms of OS[128].A parallel study of biomarkers was conducted using immunohistochemistry and NGS.The most common alteration found in HER2-positive patients was amplification ofCCNE1,which correlated with a lack of response to therapy.Patients with high levels ofERBB2amplification were more responsive to therapy.The analysis of cell-free DNA showed that the amplification ofERBB2,detectable in the plasma of patients,was a predictive response.During disease progression,genetic changes were detected such as amplification ofMYC,EGFR,FGFR2,andMET[129].A phase I clinical trial (NCT02795988) evaluated the safety,tolerability,and immunogenicity of IMU-131,a peptide composed of three epitopes selected from the protein structure of HER2.In the phase II portion of the same trial,IMU-131 was used in combination with chemotherapy in patients overexpressing HER2.The study is ongoing,as only phase I has been completed,and no conclusions have been drawn[130].Pyrotinib is an irreversible inhibitor of both HER2 and EGFR.The phase I studies (NCT02500199,NCT02378389) with pyrotinib and pyrotinib plus docetaxel in patients with HER2-positive GC are recruiting[131,132].

    Studies have also been performed to identify markers to be used in monitoring the efficacy of trastuzumab alone or in combination with chemotherapy.Resistance has occurred in patients treated with trastuzumab.One of the main mechanisms that lead to this resistance are mutations inPI3KCAandPTEN[64,65,67].The combination of trastuzumab with PI3K inhibitors may bring substantial benefits to patients with HER2-positive GC.One of the markers of resistance to trastuzumab isCCNE1,whose amplification is negatively correlated with the response to therapy directed against HER2[133].Other monoclonal antibodies used to target EGFR include cetuximab and panitumumab.The results showed that anti-EGFR antibodies did not provide further benefits for patients with advanced GC receiving chemotherapy as first-line treatment(EXPAND) (NCT00678535)[134].Panitumumab was used as first-line treatment in a clinical phase I/II trial (NCT01716546) in association with 5-FU,cisplatin,and docetaxel for locally advanced or metastatic GC.However,this study did not reach its primary endpoint because in an intermediate analysis,the number of responses obtained was lower than the prefixed limit[135].Nimotuzumab is the first EGFR humanized monoclonal antibody that binds with high specificity to the extracellular region of EGFR.Two clinical trials have been concluded.The phase III study(NCT01813253) was performed to evaluate the OS in advanced GC patients with EGFR overexpression who were treated with nimotuzumab in combination with irinotecan and compared to a group of patients who received only irinotecan.This study,completed in 2018,has not yet had its results reported[136].The second study(NCT02370849) evaluated the efficacy of cisplatin and S-1 with and without nimotuzumab in patients with advanced GC who were not previously treated[137].The combination of nimotuzumab and S-1-cisplatin provided no additional benefit compared to chemotherapy alone in the first-line treatment of unresectable or metastatic GC[138]

    mTOR/PI3K/AKT signaling pathway

    Everolimus (RAD001) is an mTOR inhibitor with antitumor activity.In a phase I clinical trial,RAD001 was used in combination with capecitabine in patients with refractory GC; the clinical benefits were modest[139].In phase I clinical trials(NCT01049620) and (NCT01042782),RAD001 was used in combination with capecitabine and oxaliplatin and with mitomycin C,respectively,in patients with advanced GC; the results of these trials are unknown[140,141].In a multicenter phase II study (NCT00519324),RAD001 was used in patients with metastatic GC with previous chemotherapy failure; particularly,10.1 mo was the median OS for which the monotherapy with everolimus,in patients in which the previous chemotherapy had failed,showed a satisfying disease control rate[142].Another clinical trial(NCT00729482) evaluated the efficacy of RAD001 as a monotherapy in patients with advanced GC in whom standard first-line treatment had failed.In addition to the efficacy of RAD001,the expression of markers was evaluated in order to identify biomarkers of response to therapy.Tumors that did not have mTOR pathway activation did not benefit from treatment with RAD001[143].The median OS was lower than that reported in the study conducted by Doiet al[142].The results of this study showed that the efficacy of RAD001 was unsatisfactory compared to conventional treatment for advanced GC[143].In the phase III GRANITE-1 study (NCT00879333),the median OS in patients treated with RAD001vsplacebo was 5.4vs4.3 mo.Compared to best supportive therapy (referred to as BSC in Table1),RAD001 did not significantly improve OS in patients with advanced GC who were previously administered one or two lines of systemic chemotherapy[144].A clinical trial(NCT01613950) was performed to investigate the efficacy of the combination of alpelisib (BYL719),a potent and selective inhibitor of mutatedPI3KCAand AUY922,an inhibitor of heat shock protein 90 (HSP90),in patients with advanced GC withPIK3CAmutations and/or amplification ofHER2,respectively.The results are not yet known[145].Ipatasertib (GDC-0068),an inhibitor of serine/threonine kinase (AKT),has been used in combination with 5-FU,folinic acid,and oxaliplatin (mFOLFOX6) in advanced or metastatic GC in a multicenter placebo-controlled clinical trial(NCT01896531).The trial is ongoing[146].

    Hepatocyte growth factor/MET signaling pathway

    High MET expression has been observed in intestinal GC rather than in the diffuse type and in advanced stage disease[147].MET positivity is a prognostic factor for OS in GC[148].Patients with GC and MET expression can benefit from anti-MET drugs.Rilotumumab is a hepatocyte growth factor (HGF) monoclonal antibody that blocks binding between HGF and its receptor MET.The efficacy of first-line rilotumumab in patients with GC in combination with ECX was demonstrated in a phase Ib/II clinical study (NCT00719550).The group of patients who received ECX plus rilotumumab showed a better prognosis than placebo[149].The RILOMET-1 clinical trial(NCT01697072) evaluated the efficacy of rilotumumab in combination with epirubicin,cisplatin,and capecitabine.Regarding OS,the addition of rilotumumab to chemotherapy did not bring about benefits compared to chemotherapy alone in MET-positive patients[150],unlike the phase II study in which OS was 10.6vs5.7 mo in MET-positive patients who received rilotumumab compared to the placebo group[149].The multicenter phase III clinical trial,RILOMET-2 (NCT02137343),in which patients with advanced GC were treated first-line with rilotumumab plus cisplatin and capecitabine,was closed for a review of the safety of the study[151].The randomized,multicenter study (NCT01662869) evaluated the efficacy of onartuzumab (monoclonal anti-MET antibody) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive GC.Onartuzumab did not yield satisfactory results in combination with FOLFOX[152].

    VEGF/VEGFR signaling pathway

    Antibodies against VEGF and VEGFR have shown anti-tumor effects in combination with chemotherapy as first and second-line treatments for GC.Bevacizumab,a humanized monoclonal antibody against VEGF,inhibits the VEGF/VEGFR signaling pathway[153].A phase II study (NCT00447330) was performed in patients with metastatic GC in combination with capecitabine and oxaliplatin; an OS of 7.2 and 10.8 mo was demonstrated in the two groups of patients treated with chemotherapy alone and with the combination with bevacizumab,respectively[154].Ramucirumab is a humanized monoclonal antibody specific for VEGFR2.By blocking downstream VEGFR2 signaling,ramucirumab provides antitumor effects both as a single agent(REGARD trial,NCT00917384)[72]and in combination with paclitaxel (RAINBOW trial,NCT01170663)[73]in patients with metastatic refractory GC.The median OS was significantly longer in the group of patients treated with ramucirumab plus paclitaxel(9.6 mo) compared to those treated with paclitaxel plus placebo (7.4 mo).Thus,ramucirumab may be a new second-line treatment for patients with metastatic GC.The addition of ramucirumab to FOLFOX (leucovorin,5-FU,oxaliplatin) did not improve OS in patients with advanced GC[155].In a phase III study (NCT01512745),apatinibvsplacebo was used in patients with advanced/metastatic GC who failed two lines of chemotherapy.The median OS was 6.5vs4.7 mo[156].Other studies with apatinib have been started but have not yet been completed regarding the use of apatinib alone as first-line maintenance treatment in patients with advanced GC(NCT03255811)[157]and as maintenance treatment with capecitabine (NCT03598348)after first-line chemotherapy[158].The clinical trial (NCT03104283) assessed the efficacy and safety of apatinib as monotherapy in elderly advanced GC patients,and determined the relationship between VEGFR2 expression and efficacy of apatinib treatment[159].In a retrospective study,the efficacy of the association of apatinib with docetaxelvsapatinib as monotherapy as a second- or third-line treatment in advanced GC was evaluated.The median OS was 3.3vs6.0 mo in patients with apatinib monotherapy and those with apatinib and docetaxel combination,respectively.Patients with advanced GC benefited more with the combination of apatinib and docetaxel than with apatinib monotherapy[160].

    TP53 signaling pathway

    A pharmacogenomic study (NCT01470404) was performed to evaluate the effects of germline polymorphisms in xenobiotic metabolism genes on the toxicity profile,and the role of germline polymorphisms of genes involved in DNA repair and theTP53tumor suppressor to predict disease recurrence and survival in GC patients treated with adjuvant chemotherapy[161].TP53mutations represent a very attractive target for cancer therapy.One of the objectives being pursued is to identify molecules that can restore the function of wild-type TP53.Among these,APR-246 was identified[162],and has already been tested in mouse models of cancer[163-165]and in phase I/II clinical trials on hematological and prostate malignancies[166].A phase I/II study(NCT02999893) was prepared for the treatment of gastroesophageal tumors with mutatedTP53[167].BecauseTP53mutations are still somewhat difficult to address adequately,identifying TP53-dependent targets may provide new opportunities for alternative targeted therapies.For example,targeting WEE1 G2 checkpoint kinase(WEE1),a protein kinase that plays a role in the G2-M cell cycle checkpoint,prevents cells from entering mitosis in response to DNA damage[168].AZD1775,an inhibitor of WEE1,was used in the clinical trial (NCT02448329) as second-line therapy in combination with paclitaxel in GC harboringTP53mutations[169].Overexpression of AURKA improves the stabilization of MDM2 and promotes the degradation of TP53,inhibiting its proapoptotic function in response to chemotherapy[79].This result justifies the use of AURKA inhibitors in the treatment of GC.The TP53/MDM2 interaction inhibitor (HDM201) was used in the clinical trial (NCT02143635) in patients with advanced GC characterized by wild-type TP53; this study is ongoing[170].No clinical trial has been performed on the use of MMP inhibitors in GC.

    PARP signaling pathway

    In response to DNA damage,sensors and effectors are activated that induce cell cycle arrest,damage repair,and eventually cell apoptosis.PARP inhibitors act by preventing breakage of the single DNA strand and induce tumor cell death[171].In vitro,gastric carcinoma cell lines,particularly those in which the ATM serine/threonine kinase expression levels are low,were sensitive to the action of olaparib (PARP inhibitor)[172].In a phase II study,the efficacy of olaparib (AZD-221)plus paclitaxel was evaluatedvspaclitaxel in patients with recurrent or metastatic GC whose ATM expression levels were low or undetectable (Study 39; NCT01063517)[173].The combination of olaparib plus paclitaxel significantly improved OS compared to placebo/paclitaxel,both in the general population and in the population with low ATM levels (13.1vs8.3 mo)[174].A multicenter phase III trial has evaluated the efficacy of olaparib in combination with paclitaxelvsplacebo plus paclitaxel in patients with advanced GC who are progressing after first-line treatment (GOLD,NCT01924533).The OS did not differ between treatment groups in the overall population (median OS 8.8 mo in the olaparib groupvs6.9 mo in the placebo group or the negative ATM population (12.0 movs10.0 mo)[173].

    The GOLD study did not achieve its primary objective to show a significant improvement in OS with olaparib in the overall or ATM-negative population of patients with advanced GC.However,the study provided data on efficacy and safety related to the use of olaparib in combination with a chemotherapy drug and the study itself is foundational for other studies in this type of patients[175].The GOLD trial has been negative for its endpoints of improved OS,both in overall patient population and the ATM-negative population.The differences between the GOLD trial and Study 39 are the enriched population of ATM-negative patients in Study 39 (51%vs19%)with respect to the GOLD study.PARP inhibitors are effective in tumors with a definite molecular signature,so it may not be realistic to expect efficacy from olaparib in an unselected marker population[176].

    Furthermore,the time of exposure to olaparib was shorter in the GOLD trial than in Study 39[177].A phase I/II pilot study was prepared to analyze the efficacy of olaparib in combination with ramucirumab in patients with metastatic,recurrent or unresectable GC (NCT03008278).The study is currently recruiting[178].Another phase I clinical trial (NCT01123876) studied the combination of veliparib (PARP inhibitor)with FOLFIRI in patients with advanced solid tumors,including GC[179].The antitumor activity of veliparib in combination with FOLFIRI and the acceptable safety profile lay the foundation for further studies.

    Immune checkpoint signaling pathway

    Pembrolizumab is the first immune checkpoint inhibitor approved by the United States Food and Drug Administration (FDA) for the treatment of advanced or metastatic GC[180].In a multicenter phase II trial (KEYNOTE-059,NCT02335411),the efficacy of pembrolizumab alone was demonstrated in patients with advanced GC who had previously been treated[181].Treatment with pembrolizumab showed a higher overall response rate in PD-L1-positive patients than in PD-L1-negative patients.Furthermore,in MSI-high patients,the response was higher than that in non-MSI high patients.These results suggest that PD-L1 and MSI levels may be predictive biomarkers of pembrolizumab efficacy[182].In the trial KEYNOTE-061 (NCT02370498),which was performed in patients with advanced PD-L1-positive GC,the efficacy of second-line treatment of pembrolizumabvspaclitaxel was compared.Pembrolizumab did not significantly improve OS compared to paclitaxel but had a better safety profile than paclitaxel[183].Pembrolizumab was used as first-line monotherapy or in combination with cisplatin,5-FU,or capecitabine in patients with advanced PD-L1-positive GC (KEYNOTE-062,NCT02494583); the results of this study are not yet known[184].In the clinical trial KEYNOTE-859 (NCT03675737),the efficacy of pembrolizumab in association with chemotherapy with cisplatin and 5-FU or oxaliplatin and capecitabine,in advanced/metastatic HER2-negative GC expressing PD-L1,will be evaluated[185].Another clinical trial (NCT02954536) is evaluating the first-line efficacy of the combination of pembrolizumab and trastuzumab in combination with chemotherapy in patients with HER2-positive metastatic GC.Preliminary results have been obtained on the safety and efficacy of the treatment.Resistance phenomena have occurred because mutations ofTP53(63%) andKRAS(16%) and loss ofERBB2amplification in disease progression have been observed[186].Nivolumab is a monoclonal antibody that targets PD-1 and has received FDA approval for neoplastic pathologies.In a clinical trial (NCT02267343) performed in patients with locally advanced or metastatic GC refractory to chemotherapy,nivolumab was effective with improvement of the median OS[187].In another clinical trial (NCT02746796),the efficacy of nivolumab in combination with chemotherapy as first-line treatment was tested in patients with advanced or recurrent non-resectable GC[188].In the clinical trial CheckMate-032 (NCT01928394),performed on solid tumors including GC,the efficacy of nivolumab in combination with ipilimumab,an anticytotoxic T-lymphocyte associated protein 4 antibody (CTLA4),was evaluated.Nivolumab with ipilimumab demonstrated encouraging long-term OS in patients with GC refractory to chemotherapy[189].In the clinical trial CheckMate-649(NCT02872116),the efficacy of nivolumab as first-line treatment in combination with ipilimumabvsnivolumab plus chemotherapyvschemotherapy alone,is being evaluated in patients with advanced or metastatic GC[190].The clinical trial(NCT03777657) is evaluating the efficacy of tislelizumab,a humanized anti-PD1,in combination with oxaliplatin and capecitabine or 5-FU and cisplatin[191].

    Other targets

    Clinical trials have been performed to study the significance of CTCs in advanced/metastatic GC.Some trials (NCT03156777[192],NCT01625702)[193]have been designed to evaluate CTCs as markers of prognosis and response to chemotherapy.In a clinical trial (NCT01625702) in HER2-positive patients,an increased HER2 extracellular domain was a predictor of a better prognosis.The elevated levels of HER2 after therapy were correlated with a negative therapeutic response[194].Other trials have been designed to evaluate CTCs and cell-free DNA as clinical prognosis markers (NCT01299688)[195]and response to HER2 (NCT02610218)[196]or VEGFR(NCT02048540)[197]targeting.Only one clinical trial (NCT01848015) was designed to establish the predictive value of CTCs in the recurrence of advanced GC after radical resection[198].Some of these trials have been completed,but the results are not yet known.A study conducted in patients with HER2-positive metastatic GC revealed that the ctDNA of these patients provided useful information for monitoring the response to trastuzumab,for the purpose of developing therapeutic strategies for HER2-positive but trastuzumab-resistant patients[199].A phase III clinical study(NCT01178944) was performed to determine if miR-215-5p levels could be predictive of the response to pralatrexate (a folate analog metabolic inhibitor) in association with oxaliplatin in patients with non-resectable GC[200].Another study (NCT03253107) was conducted to determine if miRNAs levels may be predictive biological markers for the response to chemotherapy[201].The results of these trials are not yet known.A study(NCT03057171) is ongoing on the control ofH.pylorion the expression of lncRNAs in gastrointestinal diseases including GC[202].

    CONCLUSION

    GC is the fifth most malignant tumor worldwide and the third leading cause of cancer-related deaths[7].Unfortunately,the disease becomes symptomatic in the advanced stage.GC is a complex disease whose onset is linked to a series of environmental and genetic factors[1-6].Despite the increasing knowledge and progress in drug development,due to late diagnosis and extreme intra- and inter-tumor heterogeneity,the prognosis of GC patients is poor.The heterogeneity of GC is mainly linked to genetic and epigenetic alterations,but also interactions with the microenvironment and the presence of intratumoral cellular clones.Hence,there are variations between patients and within the same tumor.The new classifications,TCGA and ACRG,based on molecular profiles and complementary to those based on pathological characteristics[15],have highlighted four GC subtypes,each characterized by specific genetic alterations[29].The molecular classification of GC has helped to identify molecular alterations that may be targeted by the therapy.Furthermore,the molecular profiles of GCs obtained from individual patients has provided new opportunities to identify biomarkers that may predict the tumor response to treatment[22-24].Unfortunately,even today,the molecular characteristics of tumors are not taken into significant consideration in the management of patients.

    H.pyloriis responsible for the onset of peptic ulcers and 80% of GC cases.Eradication of theH.pyloriinfection treats gastritis and peptic ulcers and is a mean to prevent GC.Obviously,for the treatment of the eradication of theH.pylori,guidelines have been issued by three separate authoritative groups[203-205]but none overcome the problem of resistance.Falloneet al[206]recently revised the guidelines to arrive at the best treatment options; however,GC still develops after the eradication.Many Japanese investigators have reported that the presence of severe atrophy after eradication represents a risk factor for the development of GC[207].Hence,there is a need for specific endoscopic surveillance programs for this type of patients.

    Endoscopy plays an important role in the diagnosis of GC[208].More than 90% of GC cases are reportedly revealed by biopsy-associated endoscopy.The increased use of endoscopy,thanks also to the revolutionary developments that have occurred recently and that have produced new,more sophisticated systems,has allowed highlighting of the “early” GC[209,210].Ultrasonographic endoscopy is useful for TNM staging of GC patients,having a high diagnostic value.This technique allows the patient to be managed for the most appropriate treatment,limiting the occurrence of unnecessary exploratory surgical procedures[211].Endoscopy can also be curative for early GC or used as palliative care for more advanced cases.In early GC,the endoscopic mucosal resection provides similar effects as traditional surgical resection[212,213].

    Surgical resection with adjuvant or neoadjuvant radiotherapy and chemotherapy with cisplatin,5-FU,taxane,or irinotecan,remains the most effective treatment for advanced GC.The recent MRC MAGIC/UK study (ISRCTN93793971) showed that perioperative ECF/ECX chemotherapy led to an improvement in OS and PFS in patients with resectable GC[214].Perioperative chemotherapy is the standard of care in most of Europe for localized GC with accepted ECF or ECX regimens[215].However,objective response rates to chemotherapy range from 20% to 40%,indicating variable clinical responses that are mostly likely caused by the biologic heterogeneity of the tumor.As with chemotherapy,therapeutic regimens based on targeted therapy have recently been introduced,which makes use of small molecules or monoclonal antibodies that can act on specific molecules capable of modifying molecular pathways involved in proliferation,differentiation,and cell invasion.

    Based on phase III clinical trials in patients with advanced/metastatic GC,trastuzumab (anti-HER2) and ramucirumab (anti-VEGFR2) have been approved as first- and second-line therapies in these patients[72-74,124].However,the survival of patients receiving these therapies is not very high,and with the exception of HER2,there are no markers that can be used to evaluate the response to therapy.Data from preclinical studies have shown a relationship between HER2 overexpression and activation of angiogenesis in breast cancer cells[216].A retrospective study showed significant efficacy of the combination of a biological therapy with ramucirumab with a chemotherapeutic (paclitaxel) in patients in whom trastuzumab therapy had failed[217].This study has demonstrated the crosstalk between HER2 signaling and angiogenesis in GC,which can explain tumor survival.Therefore,trastuzumab resistance could be overcome by inhibiting the angiogenic pathway.An analysis of subgroups extrapolated from the RAINBOW study showed that patients who had already been treated with trastuzumab benefited from treatment with ramucirumab in combination with paclitaxel[218].New studies will be needed to evaluate the efficacy of sequential blockades of both pathways to improve the survival of patients with GC.

    Other monoclonal antibodies,such as cetuximab and panitumumab (anti-EGFR),have also been tested in advanced/metastatic GC but the results on survival rates have not been encouraging[134-135].Unacceptable results were obtained with RAD001,an mTOR inhibitor.The efficacy of RAD001 is unsatisfactory compared to conventional treatment for advanced GCs[139,143].Anti-MET monoclonal antibodies,such as rilotumumab and onartuzumab,in combination with chemotherapy,did not bring benefits compared to chemotherapy alone[149-152].A study was prepared to more effectively target MET with a mixture of two humanized monoclonal antibodies that target two non-overlapping MET epitopes.The results represent efficacy data demonstrated on preclinical models and are part of a clinical trial (NCT02648724)[219]carried out on patients with NSLC and MET amplification[220].The advantage of antibody mixtures is their ability to orchestrate the internalization of the receptor and its degradation more effectively than a single monoclonal antibody,as previously shown for the EGFR family[221].

    PARP inhibitors are very effective in the treatment of ovarian and breast tumors in which DNA repair systems are altered and BRCA1/2 mutations are present,which makes them more sensitive to these inhibitors[222].New biomarkers are being explored,which go beyond BRCA1/2 mutations and DNA repair mechanism deficits to stratify sensitive patients,new combinations of PARP inhibitors,and/or combinations with checkpoint inhibitors to determine who will be eligible for this treatment for other solid tumors,including GC[223].It has been hypothesized that the inhibition of PARP may trigger mechanisms based on the recognition of new tumor cell antigens by the immune system,making the PARP inhibitors potential partners for combination with immune checkpoint inhibitors.

    Recently,patients with GC have also been studied from an immunotherapy viewpoint.Pembrolizumab and nivolumab received FDA approval for GC[180].Anti-PD1 antibodies have been used in phase II and phase III clinical trials and appear to be promising,especially in patients overexpressing PD-L1.Further clinical trials are underway to evaluate the efficacy of these antibodies in association with chemotherapy.At the same time,other pathways such as the TP53 signaling pathway,are being studied to identify inhibitory molecules[162-166].Strategic opportunities can also be provided by studying the potential of biomarkers such as CTCs,ctDNA,miRNAs,and lncRNAs to predict response to therapy and resistance phenomena.

    There is no doubt that targeted therapies allow patients to live longer,whether they are administered alone or in combination with chemotherapy.Today the probability of observing patients who survive several years after the diagnosis of cancer is much higher,thanks to the targeted therapies.The targeted therapies must be provided to groups of patients who can benefit from them,screened on the molecular profiles to which the therapy is effective.Molecular profiling regarding the overexpression and/or mutation of the targets must be carried out on tissue biopsies,both in resectable and unresectable patients,to establish the correct targeted therapy to be used alone or associated with chemotherapy.It is necessary to continue to study the heterogeneity of GC.The fact that GC has genetic variations between different patients and/or in the same patient during its progression and/or during or after therapy (conventional or targeted) should drive investigations into the molecular characteristics present in tumor tissue,and the use of circulating biomarkers to predict and monitor disease progression and response to therapy.Furthermore,the association of several markers should be considered in order to appropriately classify the tumor and to establish therapeutic strategies that increase survival rates.

    99热6这里只有精品| 又黄又爽又刺激的免费视频.| 亚洲自拍偷在线| 看片在线看免费视频| 国产精品久久久久久久久免| 美女黄网站色视频| 麻豆av噜噜一区二区三区| 神马国产精品三级电影在线观看| 成人欧美大片| 亚洲图色成人| 午夜精品久久久久久毛片777| 综合色av麻豆| 变态另类成人亚洲欧美熟女| 久久久久精品国产欧美久久久| 最后的刺客免费高清国语| 婷婷亚洲欧美| 午夜精品一区二区三区免费看| 久久久国产成人免费| 亚洲精品在线观看二区| 伊人久久精品亚洲午夜| 亚洲va日本ⅴa欧美va伊人久久| 成熟少妇高潮喷水视频| 高清在线国产一区| 国产精品永久免费网站| 男人和女人高潮做爰伦理| 久久天躁狠狠躁夜夜2o2o| 69av精品久久久久久| 我要看日韩黄色一级片| 国产伦人伦偷精品视频| 欧美一区二区国产精品久久精品| 床上黄色一级片| 国产午夜福利久久久久久| .国产精品久久| 亚洲av二区三区四区| 亚洲经典国产精华液单| 国产高清不卡午夜福利| 变态另类成人亚洲欧美熟女| 99热精品在线国产| 窝窝影院91人妻| 赤兔流量卡办理| 特大巨黑吊av在线直播| 最近在线观看免费完整版| 国产精品女同一区二区软件 | 亚洲内射少妇av| 免费不卡的大黄色大毛片视频在线观看 | 日日摸夜夜添夜夜添小说| 午夜久久久久精精品| 别揉我奶头~嗯~啊~动态视频| 久久久精品欧美日韩精品| 久久久久久久午夜电影| 九九久久精品国产亚洲av麻豆| 亚洲av.av天堂| 天堂√8在线中文| 国产精品一及| 国产亚洲91精品色在线| 成人特级av手机在线观看| 色综合亚洲欧美另类图片| 日韩欧美三级三区| 国产男人的电影天堂91| 丰满人妻一区二区三区视频av| 深夜精品福利| 床上黄色一级片| 国产视频一区二区在线看| 久久人妻av系列| 欧美潮喷喷水| 欧美成人免费av一区二区三区| 精品久久久久久成人av| 级片在线观看| 男女那种视频在线观看| 国内精品久久久久精免费| 成人精品一区二区免费| 欧美+日韩+精品| 国产伦一二天堂av在线观看| 特级一级黄色大片| 免费看光身美女| 亚洲专区国产一区二区| 悠悠久久av| 91久久精品电影网| 亚洲真实伦在线观看| 亚洲专区中文字幕在线| av在线观看视频网站免费| 人妻夜夜爽99麻豆av| 色5月婷婷丁香| 亚洲性久久影院| 国产精品乱码一区二三区的特点| 国产高清不卡午夜福利| 亚洲国产精品合色在线| 天堂网av新在线| 看黄色毛片网站| 欧美人与善性xxx| 欧美日韩综合久久久久久 | 国内少妇人妻偷人精品xxx网站| 大型黄色视频在线免费观看| 美女大奶头视频| 国产精品久久久久久精品电影| 长腿黑丝高跟| 校园人妻丝袜中文字幕| 69人妻影院| 黄色视频,在线免费观看| 毛片一级片免费看久久久久 | bbb黄色大片| 亚洲精品影视一区二区三区av| 亚洲国产欧美人成| 少妇丰满av| 黄片wwwwww| eeuss影院久久| 成人三级黄色视频| 男人舔女人下体高潮全视频| 免费看a级黄色片| 中文字幕av成人在线电影| 亚洲电影在线观看av| 成人高潮视频无遮挡免费网站| 成人一区二区视频在线观看| 国产大屁股一区二区在线视频| 极品教师在线视频| 91精品国产九色| 国产单亲对白刺激| 成人亚洲精品av一区二区| 国产真实乱freesex| 最近视频中文字幕2019在线8| 国产一区二区亚洲精品在线观看| 日韩欧美三级三区| 精品乱码久久久久久99久播| 日韩欧美三级三区| 国产欧美日韩精品亚洲av| 色哟哟·www| 女生性感内裤真人,穿戴方法视频| 免费不卡的大黄色大毛片视频在线观看 | 91久久精品国产一区二区三区| 18禁在线播放成人免费| 国产一区二区激情短视频| 69人妻影院| 日日干狠狠操夜夜爽| a级毛片a级免费在线| av在线天堂中文字幕| 校园人妻丝袜中文字幕| 搡老妇女老女人老熟妇| 亚洲黑人精品在线| 国模一区二区三区四区视频| 国产伦人伦偷精品视频| 亚洲av一区综合| 最近最新免费中文字幕在线| 成人性生交大片免费视频hd| 少妇人妻精品综合一区二区 | av在线亚洲专区| 国产黄片美女视频| 久久精品人妻少妇| 久久这里只有精品中国| 亚洲精品国产成人久久av| 中亚洲国语对白在线视频| 18禁黄网站禁片午夜丰满| 亚洲人成网站在线播| 联通29元200g的流量卡| 国产精品乱码一区二三区的特点| 日韩精品青青久久久久久| 国产精品一及| 免费观看人在逋| 国产大屁股一区二区在线视频| 欧美日本视频| av在线蜜桃| 欧美bdsm另类| 国产精品国产三级国产av玫瑰| 99久久无色码亚洲精品果冻| 午夜激情福利司机影院| 欧美国产日韩亚洲一区| 国产av麻豆久久久久久久| 成人国产综合亚洲| 亚洲成人久久性| 久久精品夜夜夜夜夜久久蜜豆| 国产一区二区亚洲精品在线观看| 欧美在线一区亚洲| 日韩高清综合在线| 麻豆精品久久久久久蜜桃| 欧美极品一区二区三区四区| 尾随美女入室| 亚洲成人精品中文字幕电影| 91在线精品国自产拍蜜月| 亚洲av电影不卡..在线观看| 人妻制服诱惑在线中文字幕| 婷婷色综合大香蕉| 99久久精品热视频| 国内揄拍国产精品人妻在线| 国产不卡一卡二| 欧美精品国产亚洲| 中亚洲国语对白在线视频| 亚洲国产色片| 亚洲最大成人手机在线| 午夜免费激情av| 亚洲成人久久爱视频| 一本久久中文字幕| 精品一区二区三区视频在线| 欧美色视频一区免费| 麻豆国产av国片精品| 在线免费十八禁| 熟女人妻精品中文字幕| 欧美中文日本在线观看视频| 亚洲av电影不卡..在线观看| 亚洲不卡免费看| 亚洲美女搞黄在线观看 | 亚洲国产色片| 最新在线观看一区二区三区| 性欧美人与动物交配| 欧美3d第一页| 色尼玛亚洲综合影院| 国产 一区 欧美 日韩| 如何舔出高潮| 国产单亲对白刺激| 国产淫片久久久久久久久| 亚洲av免费高清在线观看| 熟女人妻精品中文字幕| 亚洲人与动物交配视频| 色视频www国产| 干丝袜人妻中文字幕| 性欧美人与动物交配| 精品午夜福利视频在线观看一区| 国产精品永久免费网站| 九色国产91popny在线| 国产激情偷乱视频一区二区| 亚洲av成人精品一区久久| 国产在视频线在精品| 男女那种视频在线观看| 免费av观看视频| 亚洲av中文字字幕乱码综合| 18+在线观看网站| 日日摸夜夜添夜夜添小说| 亚洲,欧美,日韩| 国产精品国产高清国产av| av天堂中文字幕网| 亚洲中文字幕日韩| 亚洲一区二区三区色噜噜| 亚洲一区二区三区色噜噜| 99视频精品全部免费 在线| 小说图片视频综合网站| 欧美日韩黄片免| 亚洲av中文av极速乱 | 亚洲国产色片| 国产麻豆成人av免费视频| 精品99又大又爽又粗少妇毛片 | 日韩欧美精品v在线| 99久久精品热视频| 亚洲精品色激情综合| 国产精品三级大全| 久久精品综合一区二区三区| 俄罗斯特黄特色一大片| 一夜夜www| 精品乱码久久久久久99久播| 国产精品国产三级国产av玫瑰| 久久人人精品亚洲av| 久久热精品热| 婷婷亚洲欧美| 中文资源天堂在线| 日韩精品中文字幕看吧| av福利片在线观看| 身体一侧抽搐| 99久久久亚洲精品蜜臀av| 免费在线观看影片大全网站| 又粗又爽又猛毛片免费看| 日韩中字成人| 他把我摸到了高潮在线观看| 精品一区二区免费观看| 日本一本二区三区精品| 午夜视频国产福利| 亚洲va日本ⅴa欧美va伊人久久| 中文资源天堂在线| 一个人看的www免费观看视频| 亚洲一区二区三区色噜噜| 免费看a级黄色片| avwww免费| 欧美黑人欧美精品刺激| 国产精品日韩av在线免费观看| 99九九线精品视频在线观看视频| 狠狠狠狠99中文字幕| 国模一区二区三区四区视频| 日韩欧美精品免费久久| 麻豆成人午夜福利视频| 亚洲人成伊人成综合网2020| 欧美另类亚洲清纯唯美| 又黄又爽又刺激的免费视频.| a级一级毛片免费在线观看| 日日摸夜夜添夜夜添av毛片 | 欧美黑人欧美精品刺激| 91久久精品国产一区二区三区| 日本a在线网址| 校园春色视频在线观看| 一个人看视频在线观看www免费| 老司机深夜福利视频在线观看| 变态另类成人亚洲欧美熟女| avwww免费| 亚洲精品影视一区二区三区av| 老司机福利观看| 天天一区二区日本电影三级| 亚洲专区中文字幕在线| 男女边吃奶边做爰视频| 熟女人妻精品中文字幕| 天堂av国产一区二区熟女人妻| 国产乱人视频| 亚洲av日韩精品久久久久久密| 国产亚洲av嫩草精品影院| 欧洲精品卡2卡3卡4卡5卡区| 黄色一级大片看看| 91av网一区二区| 美女xxoo啪啪120秒动态图| 可以在线观看的亚洲视频| 国产激情偷乱视频一区二区| 日日啪夜夜撸| 一级毛片久久久久久久久女| 国产日本99.免费观看| 在线国产一区二区在线| 国产av在哪里看| 国产精品久久视频播放| 亚洲中文日韩欧美视频| 日韩中字成人| 亚洲精品久久国产高清桃花| 男女那种视频在线观看| 欧美又色又爽又黄视频| 国产精品久久久久久av不卡| 麻豆一二三区av精品| 一区福利在线观看| 狂野欧美激情性xxxx在线观看| 精品久久久久久久久久久久久| 亚洲国产精品合色在线| 国产精品人妻久久久影院| 亚洲一区高清亚洲精品| 变态另类成人亚洲欧美熟女| 免费av毛片视频| 久久午夜亚洲精品久久| 亚洲av中文字字幕乱码综合| 亚洲中文字幕日韩| 欧美性猛交黑人性爽| 老司机午夜福利在线观看视频| 看免费成人av毛片| 男女边吃奶边做爰视频| 性欧美人与动物交配| 免费看光身美女| 村上凉子中文字幕在线| 欧美激情在线99| 日本黄色片子视频| 国产亚洲精品综合一区在线观看| 成人av一区二区三区在线看| 亚洲熟妇熟女久久| 国产精品嫩草影院av在线观看 | 日本撒尿小便嘘嘘汇集6| 日韩一区二区视频免费看| 国产极品精品免费视频能看的| 婷婷色综合大香蕉| 69人妻影院| 亚洲欧美精品综合久久99| 久久久久久久久久成人| 日日啪夜夜撸| 亚洲精品国产成人久久av| 两个人视频免费观看高清| 色视频www国产| 看黄色毛片网站| 波多野结衣高清无吗| 亚洲av免费在线观看| 久久久久九九精品影院| 欧美极品一区二区三区四区| 成人精品一区二区免费| 麻豆久久精品国产亚洲av| 日韩欧美三级三区| 日本欧美国产在线视频| 亚洲天堂国产精品一区在线| 动漫黄色视频在线观看| 99热网站在线观看| 亚洲最大成人手机在线| 淫妇啪啪啪对白视频| 人妻夜夜爽99麻豆av| 亚洲内射少妇av| 在线免费观看不下载黄p国产 | 久久久久久久久大av| www.www免费av| 九色国产91popny在线| 一个人看的www免费观看视频| 久久精品国产亚洲av香蕉五月| 成人无遮挡网站| 国产高清三级在线| 一级a爱片免费观看的视频| 久久国内精品自在自线图片| 人妻丰满熟妇av一区二区三区| 日韩一本色道免费dvd| 国产一区二区三区在线臀色熟女| 天堂影院成人在线观看| 男女啪啪激烈高潮av片| 久久午夜福利片| 午夜视频国产福利| 国内精品久久久久精免费| 欧美+亚洲+日韩+国产| а√天堂www在线а√下载| 欧美一级a爱片免费观看看| 99国产极品粉嫩在线观看| av视频在线观看入口| 中文在线观看免费www的网站| 精品一区二区三区人妻视频| 欧美性猛交╳xxx乱大交人| 日本三级黄在线观看| 久久香蕉精品热| 亚洲av日韩精品久久久久久密| 两人在一起打扑克的视频| 久久香蕉精品热| 日韩强制内射视频| 尤物成人国产欧美一区二区三区| 国产高清视频在线播放一区| 日韩强制内射视频| 别揉我奶头 嗯啊视频| 亚洲av五月六月丁香网| 精品一区二区免费观看| 可以在线观看的亚洲视频| 少妇高潮的动态图| 九色成人免费人妻av| 老司机福利观看| 麻豆久久精品国产亚洲av| 国产黄色小视频在线观看| 又黄又爽又刺激的免费视频.| 日本与韩国留学比较| a在线观看视频网站| 在线播放无遮挡| 国产精品av视频在线免费观看| 真人一进一出gif抽搐免费| 久久久久久久久久成人| 天堂√8在线中文| 久久精品国产亚洲av天美| 精品人妻偷拍中文字幕| 久久久久久久精品吃奶| 99精品在免费线老司机午夜| eeuss影院久久| 久9热在线精品视频| 人妻制服诱惑在线中文字幕| АⅤ资源中文在线天堂| 国产精品久久久久久久久免| 午夜福利在线观看免费完整高清在 | 国产一区二区三区av在线 | 欧美不卡视频在线免费观看| 欧美黑人欧美精品刺激| 夜夜夜夜夜久久久久| 又紧又爽又黄一区二区| 国产精品自产拍在线观看55亚洲| 极品教师在线视频| 亚洲成人久久性| 亚洲黑人精品在线| 欧美最黄视频在线播放免费| 亚洲精品成人久久久久久| 国内精品宾馆在线| 搞女人的毛片| 日韩欧美三级三区| 国产亚洲欧美98| 999久久久精品免费观看国产| 中文字幕熟女人妻在线| 国产精品久久电影中文字幕| 天天一区二区日本电影三级| 国产黄a三级三级三级人| 老司机福利观看| 久久久午夜欧美精品| 国产亚洲av嫩草精品影院| 欧美绝顶高潮抽搐喷水| 久久久久久久久久黄片| 91麻豆av在线| 精品午夜福利视频在线观看一区| 日韩国内少妇激情av| av在线观看视频网站免费| 欧美成人一区二区免费高清观看| 在线观看舔阴道视频| 亚洲18禁久久av| 91麻豆av在线| 一级黄色大片毛片| 黄色视频,在线免费观看| 亚洲在线自拍视频| 日韩中字成人| 精品人妻熟女av久视频| 精品福利观看| 九色成人免费人妻av| 亚洲avbb在线观看| 日本免费一区二区三区高清不卡| 制服丝袜大香蕉在线| 国产成人a区在线观看| 欧美日韩精品成人综合77777| 日本欧美国产在线视频| 国产黄片美女视频| 亚洲狠狠婷婷综合久久图片| 成熟少妇高潮喷水视频| 亚洲美女黄片视频| 一进一出抽搐动态| 国产精品一区二区三区四区免费观看 | 成人欧美大片| 免费电影在线观看免费观看| 亚洲av不卡在线观看| 亚洲av中文av极速乱 | 成人国产综合亚洲| 亚洲精品国产成人久久av| 一本精品99久久精品77| 日韩欧美精品v在线| 狂野欧美白嫩少妇大欣赏| 国产精品98久久久久久宅男小说| 亚洲国产欧美人成| 黄色丝袜av网址大全| 午夜影院日韩av| 男人和女人高潮做爰伦理| 亚洲中文日韩欧美视频| 成人国产麻豆网| 国产真实乱freesex| 99视频精品全部免费 在线| 一区二区三区四区激情视频 | 成人特级av手机在线观看| 国内久久婷婷六月综合欲色啪| 一级a爱片免费观看的视频| 春色校园在线视频观看| 在线a可以看的网站| 嫩草影院新地址| 美女被艹到高潮喷水动态| 国产免费av片在线观看野外av| 干丝袜人妻中文字幕| 1000部很黄的大片| 中亚洲国语对白在线视频| 搡老熟女国产l中国老女人| 99热只有精品国产| 12—13女人毛片做爰片一| 日本免费a在线| 日日摸夜夜添夜夜添小说| 高清日韩中文字幕在线| 老司机午夜福利在线观看视频| av天堂在线播放| 午夜爱爱视频在线播放| 又紧又爽又黄一区二区| 亚洲狠狠婷婷综合久久图片| 亚洲欧美日韩高清在线视频| 搡女人真爽免费视频火全软件 | 丰满人妻一区二区三区视频av| 成人鲁丝片一二三区免费| 欧美一区二区精品小视频在线| videossex国产| 成人高潮视频无遮挡免费网站| 国产精品爽爽va在线观看网站| a级一级毛片免费在线观看| 国产精品国产三级国产av玫瑰| 亚洲av不卡在线观看| 亚洲真实伦在线观看| 国产精品美女特级片免费视频播放器| 夜夜看夜夜爽夜夜摸| 夜夜爽天天搞| 国产伦在线观看视频一区| 国产一区二区亚洲精品在线观看| 国产aⅴ精品一区二区三区波| 国产免费av片在线观看野外av| 精品午夜福利视频在线观看一区| 国产精品久久久久久亚洲av鲁大| 99在线视频只有这里精品首页| 亚洲人成网站在线播放欧美日韩| 丝袜美腿在线中文| 搞女人的毛片| 偷拍熟女少妇极品色| netflix在线观看网站| 成年女人永久免费观看视频| 国产色婷婷99| 日日撸夜夜添| 亚洲第一电影网av| 香蕉av资源在线| 国产又黄又爽又无遮挡在线| 我的女老师完整版在线观看| 欧美成人免费av一区二区三区| 男女啪啪激烈高潮av片| av女优亚洲男人天堂| 免费观看在线日韩| 18禁裸乳无遮挡免费网站照片| 国产黄片美女视频| 亚洲国产精品成人综合色| 99久久九九国产精品国产免费| 男女之事视频高清在线观看| 午夜日韩欧美国产| 国产成人福利小说| 成人综合一区亚洲| 亚洲综合色惰| 又爽又黄无遮挡网站| 亚洲美女黄片视频| 桃色一区二区三区在线观看| 免费看a级黄色片| 韩国av在线不卡| 婷婷精品国产亚洲av在线| 午夜激情欧美在线| 国产三级中文精品| 欧美xxxx性猛交bbbb| 1000部很黄的大片| 亚洲国产色片| 欧美一区二区精品小视频在线| 99精品久久久久人妻精品| 三级国产精品欧美在线观看| 久9热在线精品视频| 久久热精品热| 亚洲人与动物交配视频| 国产乱人视频| 在线免费观看不下载黄p国产 | 日本欧美国产在线视频| 色哟哟哟哟哟哟| 久久九九热精品免费| 国产一区二区三区视频了| 国产欧美日韩一区二区精品| 麻豆久久精品国产亚洲av| 能在线免费观看的黄片| 在线观看av片永久免费下载| 99精品久久久久人妻精品| 成人毛片a级毛片在线播放| av女优亚洲男人天堂| 久久久久久九九精品二区国产| 乱系列少妇在线播放| 日韩欧美国产一区二区入口| 亚洲人成伊人成综合网2020| 亚洲乱码一区二区免费版| 精品午夜福利视频在线观看一区| 日韩中字成人| 别揉我奶头 嗯啊视频| 亚洲美女视频黄频| 精品人妻一区二区三区麻豆 | 白带黄色成豆腐渣| 亚洲精品影视一区二区三区av| 小说图片视频综合网站| 男插女下体视频免费在线播放| 亚洲中文字幕一区二区三区有码在线看|